Company profile: Epiva
1.1 - Company Overview
Company description
- Provider of immuno-microbiome therapeutics, developing immunobiotic therapeutics through a platform from Flagship VentureLabs, the innovation foundry of Flagship Ventures.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Epiva
TRex Bio
HQ: United States
Website
- Description: Provider of a deep biology platform that maps human tissue regulatory T cell behavior to disease using high-resolution sequencing, computational biology and translational assays to identify targets, and developer of therapeutics for cancer, fibrotic and immune-mediated diseases, including TRB-061 (TNFR2 agonist; IND-enabling, FIH 2025), TRB-031/-041 (with Eli Lilly; lead optimization) and TRB-071/-081 (target ID/validation).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TRex Bio company profile →
Cellenkos
HQ: United States
Website
- Description: Provider of clinical-stage allogeneic cord blood regulatory T cell therapeutics for autoimmune and inflammatory disorders, enabled by the proprietary CRANE platform for cell enrichment and differentiation and in-house cGMP manufacturing. Pipeline includes CK0801 for bone marrow failure syndromes, CK0802 for COVID-19 ARDS, and CK0804 for myelofibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellenkos company profile →
OMass Therapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery leveraging novel mass spectrometry, offering the OdyssION platform that uses native mass spectrometry and custom chemistry to study target interactions in native ecosystems, and a small molecule pipeline targeting solute carriers, inflammasome complexes, and GPCRs for orphan and immunological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OMass Therapeutics company profile →
Phadia
HQ: Sweden
Website
- Description: Provider of complete blood test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; develops, manufactures and markets these systems, with more than 40 years of leadership in allergy testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phadia company profile →
Telavant
HQ: United States
Website
- Description: Provider of novel medicines in development to assist patients suffering from inflammatory and fibrotic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Telavant company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Epiva
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Epiva
2.2 - Growth funds investing in similar companies to Epiva
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Epiva
4.2 - Public trading comparable groups for Epiva
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →